Explore the words cloud of the SAVEBRAIN project. It provides you a very rough idea of what is the project "SAVEBRAIN" about.
The following table provides information about the project.
|Coordinator Country||Netherlands [NL]|
|Total cost||149˙993 €|
|EC max contribution||149˙993 € (100%)|
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
|Duration (year-month-day)||from 2018-04-01 to 2019-09-30|
Take a look of project's partnership.
|1||UNIVERSITEIT MAASTRICHT||NL (MAASTRICHT)||coordinator||51˙896.00|
|2||FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V.||DE (MUNCHEN)||participant||78˙097.00|
|3||MUCKE HERMANN||AT (WIEN)||participant||19˙999.00|
Stroke represents currently one of the largest – if not the largest - unmet medical need: It is the second leading cause of death and the leading cause of disability. In contrast to this high demand for effective treatments, there is only one drug available, a blood-clot dissolving agent. However, this drug is marginally effective has over 30 contra-indications, and bears an extremely high risk of causing fatal bleeding that 85% of all stroke patients are not treated with it. The needed innovation would be a drug which is broadly applicable, i.e. has no contraindication, can be given in all forms of stroke and already in the ambulance, is safe, i.e. bears no risk to cause secondary bleeding, is effective, i.e. reduces the brain infarct, increases survival and improves neurological outcomes for patients, has a different mechanism of action, i.e. is directly neuroprotective. Our therapeutic principle, discovered in the course of the ERC-ADG RadMed fulfils all above criteria and is also commercially an innovative approach because we reduce the risk by developing only a single compound by here combining three compounds that target the same disease mechanism but at different points. We thereby expect to dramatically reduce the likelihood risk of failure in our post-proof of concept (PoC) clinical development and commercialisation process. We here propose to conduct the final step, the PoC, before a first-in-man study in stroke. Our PoC plan has three major objectives: To complete an IPR FTPO and Foreground analysis, to chose the optimal compounds and complete phase III pre-clinical to provide PoC for a first-in-man trial in stroke, to then allow the work-out of a complete business plan including competitive analysis, development strategy, and commercial/business development strategy.
|year||authors and title||journal||last update|
Ana I. Casas, Pamela W.M. Kleikers, Eva Geuss, Friederike Langhauser, Thure Adler, Dirk H. Busch, Valerie Gailus-Durner, Martin HrabÃª de Angelis, Javier Egea, Manuela G. Lopez, Christoph Kleinschnitz, Harald H.H.W. Schmidt
Calcium-dependent blood-brain barrier breakdown by NOX5 limits postreperfusion benefit in stroke
published pages: 1772-1778, ISSN: 0021-9738, DOI: 10.1172/jci124283
|Journal of Clinical Investigation 129/4||2020-04-03|
Ana I. Casas, Ahmed A. Hassan, Simon J. Larsen, Vanessa Gomez-Rangel, Mahmoud Elbatreek, Pamela W. M. Kleikers, Emre Guney, Javier Egea, Manuela G. LÃ³pez, Jan Baumbach, Harald H. H. W. Schmidt
From single drug targets to synergistic network pharmacology in ischemic stroke
published pages: 7129-7136, ISSN: 0027-8424, DOI: 10.1073/pnas.1820799116
|Proceedings of the National Academy of Sciences 116/14||2020-04-03|
Ana I. Casas, Eva Geuss, Pamela W. M. Kleikers, Stine Mencl, Alexander M. Herrmann, Izaskun Buendia, Javier Egea, Sven G. Meuth, Manuela G. Lopez, Christoph Kleinschnitz, Harald H. H. W. Schmidt
NOX4-dependent neuronal autotoxicity and BBB breakdown explain the superior sensitivity of the brain to ischemic damage
published pages: 12315-12320, ISSN: 0027-8424, DOI: 10.1073/pnas.1705034114
|Proceedings of the National Academy of Sciences 114/46||2019-04-03|
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SAVEBRAIN" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "SAVEBRAIN" are provided by the European Opendata Portal: CORDIS opendata.
High throughput multiplexed trace-analyte screening for diagnostics applicationsRead More
A need for speed: mechanisms to coordinate protein synthesis and folding in metazoansRead More
Dynamic Modeling of Labor Market Mobility and Human Capital AccumulationRead More